Literature DB >> 9041413

An optimized PCR leads to rapid and highly sensitive detection of Borrelia burgdorferi in patients with Lyme borreliosis.

S Priem1, M G Rittig, T Kamradt, G R Burmester, A Krause.   

Abstract

The present study aimed at developing an optimized PCR protocol fro the sensitive and specific detection of all three Borrelia burgdorferi genospecies pathogenic to humans in Lyme borreliosis patients. A rapid DNA extraction method using alkaline lysis was introduced and was found to be superior to other DNA extraction methods. Nested PCR was performed with primer sets targeting the plasmid-located ospA gene and a chromosomal gene segment encoding a 66-kDa protein (p66). In spiked synovial fluid (SF) fewer than three borreliae/sample were detected. The specificities of the amplicons were confirmed by Southern blot analysis with PCR-derived probes. Urine, cerebrospinal fluid (CSF), and SF specimens from 57 patients with Lyme borreliosis and from 58 controls were examined. In clinical samples the diagnostic sensitivity of PCR was 85% with SF samples, 79% with urine samples, and 91% with paired SF-urine samples from patients with Lyme arthritis and was 79% with CSF samples, 45% with urine samples, and 87% with paired CSF-urine specimens from neuroborreliosis patients. One patient each with neuroborreliosis and with Lyme arthritis had PCR-positive urine samples only. In 17% of all cases both primer sets yielded positive results, while the other patients were positive with only one primer set. Among these, more positive results were obtained with the p66 gene primer than with the ospA primer. The specificity exceeded 99%. We conclude that DNA from B. burgdorferi sensu lato species can sensitively and specifically be detected with the optimized PCR method described. At least two different primer sets should be used, and whenever possible, urine and CSF or SF should be analyzed in parallel to achieve maximum sensitivity of the test. This protocol, therefore, considerably enhances the diagnostic power of PCR in patients with B. burgdorferi infection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9041413      PMCID: PMC229651          DOI: 10.1128/jcm.35.3.685-690.1997

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  37 in total

1.  Producing single-stranded DNA probes with the Taq DNA polymerase: a high yield protocol.

Authors:  U Finckh; P A Lingenfelter; D Myerson
Journal:  Biotechniques       Date:  1991-01       Impact factor: 1.993

2.  Detection of Borrelia burgdorferi in patients with Lyme disease by the polymerase chain reaction.

Authors:  E C Guy; G Stanek
Journal:  J Clin Pathol       Date:  1991-07       Impact factor: 3.411

3.  The Borrelia burgdorferi flagellum-associated 41-kilodalton antigen (flagellin): molecular cloning, expression, and amplification of the gene.

Authors:  R Wallich; S E Moter; M M Simon; K Ebnet; A Heiberger; M D Kramer
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

4.  T cell proliferation induced by Borrelia burgdorferi in patients with Lyme borreliosis. Autologous serum required for optimum stimulation.

Authors:  A Krause; V Brade; C Schoerner; W Solbach; J R Kalden; G R Burmester
Journal:  Arthritis Rheum       Date:  1991-04

5.  Molecular diagnosis of Borrelia burgdorferi infection (Lyme disease).

Authors:  W V Williams; P Callegari; B Freundlich; G Keenan; D Eldridge; H Shin; M Kreitman; D McCallus; D B Weiner
Journal:  DNA Cell Biol       Date:  1992-04       Impact factor: 3.311

6.  A specific and sensitive assay for the Lyme disease spirochete Borrelia burgdorferi using the polymerase chain reaction.

Authors:  P A Rosa; T G Schwan
Journal:  J Infect Dis       Date:  1989-12       Impact factor: 5.226

7.  Rapid detection of human cytomegalovirus DNA in peripheral blood leukocytes of viremic transplant recipients by the polymerase chain reaction.

Authors:  N M Jiwa; G W Van Gemert; A K Raap; F M Van de Rijke; A Mulder; P F Lens; M M Salimans; F E Zwaan; W Van Dorp; M Van der Ploeg
Journal:  Transplantation       Date:  1989-07       Impact factor: 4.939

8.  Molecular subtyping of Borrelia burgdorferi in erythema migrans and acrodermatitis chronica atrophicans.

Authors:  R Wienecke; N Zöchling; U Neubert; E M Schlüpen; M Meurer; M Volkenandt
Journal:  J Invest Dermatol       Date:  1994-07       Impact factor: 8.551

9.  Molecular detection of persistent Borrelia burgdorferi in the urine of patients with active Lyme disease.

Authors:  J L Goodman; P Jurkovich; J M Kramber; R C Johnson
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

10.  PCR detection of Borrelia burgdorferi DNA in cerebrospinal fluid of Lyme neuroborreliosis patients.

Authors:  T L Keller; J J Halperin; M Whitman
Journal:  Neurology       Date:  1992-01       Impact factor: 9.910

View more
  30 in total

1.  Global Tn-seq analysis of carbohydrate utilization and vertebrate infectivity of Borrelia burgdorferi.

Authors:  Erin B Troy; Tao Lin; Lihui Gao; David W Lazinski; Maureen Lundt; Andrew Camilli; Steven J Norris; Linden T Hu
Journal:  Mol Microbiol       Date:  2016-07-15       Impact factor: 3.501

2.  Detection of Borrelia burgdorferi DNA in urine of patients with ocular Lyme borreliosis.

Authors:  U Pleyer; S Priem; L Bergmann; G Burmester; C Hartmann; A Krause
Journal:  Br J Ophthalmol       Date:  2001-05       Impact factor: 4.638

3.  Rapid typing of Borrelia burgdorferi sensu lato species in specimens from patients with different manifestations of Lyme borreliosis.

Authors:  J D Lünemann; S Zarmas; S Priem; J Franz; R Zschenderlein; E Aberer; R Klein; L Schouls; G R Burmester; A Krause
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

4.  Improved method of detection and molecular typing of Borrelia burgdorferi sensu lato in clinical samples by polymerase chain reaction without DNA purification.

Authors:  N Rudenko; M Golovchenko; J Nemec; J Volkaert; N Mallátová; L Grubhoffer
Journal:  Folia Microbiol (Praha)       Date:  2005       Impact factor: 2.099

5.  T2 Magnetic Resonance Assay-Based Direct Detection of Three Lyme Disease-Related Borrelia Species in Whole-Blood Samples.

Authors:  Jessica L Snyder; Heidi Giese; Cheryl Bandoski-Gralinski; Jessica Townsend; Beck E Jacobson; Robert Shivers; Anna M Schotthoefer; Thomas R Fritsche; Clayton Green; Steven M Callister; John A Branda; Thomas J Lowery
Journal:  J Clin Microbiol       Date:  2017-05-31       Impact factor: 5.948

6.  Detection and molecular typing of Borrelia burgdorferi sensu lato in Ixodes ricinus ticks and in different patient samples from southwest Germany.

Authors:  D Schaarschmidt; R Oehme; P Kimmig; R D Hesch; S Englisch
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

7.  Identification of three clinically relevant Borrelia burgdorferi sensu lato genospecies by PCR-restriction fragment length polymorphism analysis of 16S-23S ribosomal DNA spacer amplicons.

Authors:  Renate Ranka; Antra Bormane; Kristine Salmina; Viesturs Baumanis
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

8.  Diagnostic value of PCR for detection of Borrelia burgdorferi in skin biopsy and urine samples from patients with skin borreliosis.

Authors:  S Brettschneider; H Bruckbauer; N Klugbauer; H Hofmann
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

9.  An ospA-polymerase chain reaction/restriction fragment length polymorphism-based method for sensitive detection and reliable differentiation of all European Borrelia burgdorferi sensu lato species and OspA types.

Authors:  H Michel; B Wilske; G Hettche; G Göttner; C Heimerl; U Reischl; U Schulte-Spechtel; V Fingerle
Journal:  Med Microbiol Immunol       Date:  2003-09-12       Impact factor: 3.402

10.  In vitro conversion of Borrelia burgdorferi to cystic forms in spinal fluid, and transformation to mobile spirochetes by incubation in BSK-H medium.

Authors:  O Brorson; S H Brorson
Journal:  Infection       Date:  1998 May-Jun       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.